Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Examples of efficacy from dose escalation studies

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Oct 01, 2021 12:47pm

127 Views

Post# 33952766

RE:RE:RE:RE:RE:RE:RE:RE:Examples of efficacy from dose escalation studies

Edit: "I have to believe all those scientific studies since they were done in HUMANS (not studies)."

Wino115 wrote: I would also point out that some of what may come from a dose escalation and even the extension trial that is perceived as "negative" is something that would not derail the SORT1 program completely. For instance, it they see it really only works best in late stage, or in mTNBC or where SORT1 was expressed at a super high level, then that's knowledge to ascertain the conditions the drug suceeds best in. It could shrink your market, but still produce a very valuable treatment option and revenue stream.

Also, you could see the toxin was "meh" --it got in the tumors but didn't do much more than the normal docetaxol approach. So then you try other toxins --you don't stop the program. They've said they will be trying others. Setback, yes -- but not a program killer. They've already mentioned immunotherapy drugs, S38 and maybe they'll get to radionuclear payloads like JFM envisions. It can definitely have roadblocks, but there are ways around most of them. The biggest roadblock would revolve around sortilin as a receptor and target. The entire program revolves around the studies that have shown it's overexpressed in relation to how advanced your cancer is. I have to believe all those scientific studies since they were done in studies. But I'd also like to see our boys replicate that in humans too.